Genetic Technology Alert. Molecular Diagnostic Test for Non-Metastatic Triple-Negative Breast Cancer; Gene Therapy for Treatment of Hearing Loss; Rapid Detection of Ebola through a Suitcase Kit

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles a molecular diagnostic test for non-metastatic triple-negative breast cancer, gene therapy for treatment of hearing loss, and rapid detection of Ebola through a suitcase kit.

Table of Contents

Genetic Technology Alert. Molecular Diagnostic Test for Non-Metastatic Triple-Negative Breast Cancer; Gene Therapy for Treatment of Hearing Loss; Rapid Detection of Ebola through a Suitcase KitIn This Issue1. MOLECULAR DIAGNOSTIC TEST FOR NON-METASTATIC TRIPLE-NEGATIVE BREAST CANCER2. GENE THERAPY FOR TREATMENT OF HEARING LOSS3. RAPID DETECTION OF EBOLA THROUGH A SUITCASE KIT4. RECENT PATENTS IN GENETIC TECHNOLOGY IN EUROPE




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.